
Diversity Day 2026 at TWINCORE
Diverse Origins – One Goal

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Diab-Elschahawi M, Kirk T, Häussler S, Presterl E, The Psps Working Group
Samuelsen Ø, López-Causapé C, Aarestrup F, Bortolaia V, Brouwer M, Cantón R, Egli A, Grad Y, Hamprecht A, Haussler S, Holt K, Hopkins K, Howden B, Jeannot K, Kahlmeter G, Köser C, Mathers A, Naas T, Pournaras S, Ruppé E, Schön T, Stoesser N, Turnidge J, Werner G, Wright G, Giske C, Oliver A
Meeder E, Xun J, Navas A, van Eekeren L, Blaauw M, Groenendijk A, Vos W, Joosten L, Netea M, de Mast Q, Blok W, Verbon A, Berrevoets M, Vadaq N, Matzaraki V, Xu C, Schellekens A, van der Ven A
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
The project will investigate the immunological and genetic causes of vaccination failure in 5% of HBV-vaccinated individuals in order to develop new strategies to improve vaccination protection.
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
"Challenge Orphan medicines – learnings from the past"
Prof. John Schoggins
Soutwestern Medical Center
University of Texas
"Mechanisms and consequences of antiviral interferon-induced effectors"
Prof. Dr. med. Axel Hamprecht
Institute of Medical Microbiology and Virology
Carl von Ossietzky Universität Oldenburg
"Carbapenemase-producing Enterobacterales - Molecular Characterization and Diagnostic Tools for the Early Detection of a Silent Epidemic"

